Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information.

Stürmer T, Glynn RJ, Rothman KJ, Avorn J, Schneeweiss S.

Med Care. 2007 Oct;45(10 Supl 2):S158-65. Review.

2.

Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.

Uddin MJ, Groenwold RH, Ali MS, de Boer A, Roes KC, Chowdhury MA, Klungel OH.

Int J Clin Pharm. 2016 Jun;38(3):714-23. doi: 10.1007/s11096-016-0299-0. Epub 2016 Apr 18. Review.

PMID:
27091131
3.

Indications for propensity scores and review of their use in pharmacoepidemiology.

Glynn RJ, Schneeweiss S, Stürmer T.

Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):253-9. Review.

4.

Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations.

Kim DH, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):891-901. doi: 10.1002/pds.3674. Epub 2014 Jun 24. Review.

5.

A tutorial on the use of instrumental variables in pharmacoepidemiology.

Ertefaie A, Small DS, Flory JH, Hennessy S.

Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):357-367. doi: 10.1002/pds.4158. Epub 2017 Feb 27. Review.

PMID:
28239929
6.

Use of disease risk scores in pharmacoepidemiologic studies.

Arbogast PG, Ray WA.

Stat Methods Med Res. 2009 Feb;18(1):67-80. doi: 10.1177/0962280208092347. Epub 2008 Jun 18. Review.

PMID:
18562398
7.

Efficient sampling approaches to address confounding in database studies.

Hanley JA, Dendukuri N.

Stat Methods Med Res. 2009 Feb;18(1):81-105. doi: 10.1177/0962280208096046. Epub 2008 Sep 24. Review.

PMID:
18815164
8.

Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.

Etminan M, Samii A.

Pharmacotherapy. 2004 Aug;24(8):964-9. Review.

PMID:
15338844
9.

[Bias and confounding: pharmacoepidemiological study using administrative database].

Nojiri S.

Yakugaku Zasshi. 2015;135(6):793-808. doi: 10.1248/yakushi.15-00006. Review. Chinese.

10.

The causes and effects of socio-demographic exclusions from clinical trials.

Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P.

Health Technol Assess. 2005 Oct;9(38):iii-iv, ix-x, 1-152. Review.

11.

Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review.

Streeter AJ, Lin NX, Crathorne L, Haasova M, Hyde C, Melzer D, Henley WE.

J Clin Epidemiol. 2017 Apr 28. pii: S0895-4356(16)30334-1. doi: 10.1016/j.jclinepi.2017.04.022. [Epub ahead of print] Review.

12.

Risks and benefits of (pharmaco)epidemiology.

Wise L.

Ther Adv Drug Saf. 2011 Jun;2(3):95-102. doi: 10.1177/2042098611404920. Review.

Supplemental Content

Support Center